Advances in Cardiovascular Therapeutics: Trends in ACE Inhibition
Volume 2
Issue 1 Suppl
Do All Patients Deserve Treatment with Angiotensin Converting Enzyme Inhibitors after Myocardial Infarction? An Argument to Treat only High-Risk Patients
The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.